MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma
©2023 American Association for Cancer Research..
SUMMARY: In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint. See related article by Paiva et al., p. 365 (1).
| Errataetall: |
CommentOn: Blood Cancer Discov. 2023 Sep 1;4(5):365-373. - PMID 37486974 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Blood cancer discovery - 4(2023), 5 vom: 01. Sept., Seite 346-348 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Landgren, Ola [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8PX1X7UG4D |
|---|
| Anmerkungen: |
Date Completed 04.09.2023 Date Revised 02.03.2024 published: Print CommentOn: Blood Cancer Discov. 2023 Sep 1;4(5):365-373. - PMID 37486974 Citation Status MEDLINE |
|---|
| doi: |
10.1158/2643-3230.BCD-23-0134 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361531931 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361531931 | ||
| 003 | DE-627 | ||
| 005 | 20240302232301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1158/2643-3230.BCD-23-0134 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1314.xml |
| 035 | |a (DE-627)NLM361531931 | ||
| 035 | |a (NLM)37655402 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Landgren, Ola |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.09.2023 | ||
| 500 | |a Date Revised 02.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentOn: Blood Cancer Discov. 2023 Sep 1;4(5):365-373. - PMID 37486974 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ©2023 American Association for Cancer Research. | ||
| 520 | |a SUMMARY: In this issue, Paiva and colleagues characterize the dynamics of minimal residual disease (MRD) and clinical responses during chimeric antigen receptor (CAR) T-cell therapy of relapsed/refractory multiple myeloma. Although both correlate with prolonged progression-free survival, MRD is reached faster in the bone marrow than complete response in peripheral blood; consequently, the study addresses the need for future guidelines to explore new MRD-negative definitions that are independent of the monoclonal (M) protein to overcome this limitation, particularly in clinical trials using early depth of response as an endpoint. See related article by Paiva et al., p. 365 (1) | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a idecabtagene vicleucel |2 NLM | |
| 650 | 7 | |a 8PX1X7UG4D |2 NLM | |
| 650 | 7 | |a Receptors, Chimeric Antigen |2 NLM | |
| 700 | 1 | |a Kazandjian, Dickran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer discovery |d 2020 |g 4(2023), 5 vom: 01. Sept., Seite 346-348 |w (DE-627)NLM31368555X |x 2643-3249 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2023 |g number:5 |g day:01 |g month:09 |g pages:346-348 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1158/2643-3230.BCD-23-0134 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2023 |e 5 |b 01 |c 09 |h 346-348 | ||